Holen Sie sich die Stockscreener-App
170.68
3.06%
5.07
Handel nachbörslich:
170.73
0.05
+0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$165.61
Offen:
$170.25
24-Stunden-Volumen:
11.29M
Relative Volume:
1.69
Marktkapitalisierung:
$211.64B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
23.22
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+9.38%
1M Leistung:
+14.51%
6M Leistung:
+30.45%
1J Leistung:
+44.11%
1-Tages-Spanne:
$169.00
$175.65
1-Wochen-Bereich:
$155.76
$175.65
52-Wochen-Spanne:
$114.02
$175.65
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
170.68 | 211.64B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,417.54 | 1.26T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.20 | 657.68B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
294.89 | 521.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.52 | 368.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
160.79 | 303.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-07-06 | Hochstufung | HSBC Securities | Hold → Buy |
| 2026-05-20 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth - Zacks Investment Research
GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks - Zacks Investment Research
Gilead Sciences (GILD) Reports Strong Q3 2026 Sales Growth, Rais - GuruFocus
Gilead Sciences Inc (GILD) (Q3 2026) Earnings Call Highlights: Base Business Surges 16% as HIV ... - Yahoo Finance
What Gilead Sciences (GILD) Said on Its Q3 Earnings Call - Yahoo Finance
Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Zacks Investment Research
Gilead Sciences, Inc. (GIS.F) Seasonal Returns ChartYahoo Finance - Yahoo! Finance Canada
Gilead Sciences, Inc. (GILD.VI) Seasonal returns chart - Yahoo Finance Australia
Gilead Sciences, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:GILD) 2026-10-29 - Seeking Alpha
Gilead Sciences, Inc. (GILD) Seasonal returns chart - Yahoo Finance UK
Gilead Sciences, Inc. (GILD.MX) Seasonal returns chart - Yahoo Finance Australia
Gilead Sciences, Inc. (GILD) Seasonal Returns ChartYahoo Finance - Yahoo! Finance Canada
Gilead Sciences, Inc. reports results for the quarter ended September 30Earnings Summary - TradingView
Gilead Sciences Q3 2026 Earnings Call Transcript - Benzinga
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade - Investor's Business Daily
A Look at Gilead Sciences Inc (GILD) After 4.0% Gain -- GF Value $107.30 vs Price $165.61 - GuruFocus
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength - WSJ
Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations - Yahoo Finance
Gilead: Q3 Earnings Snapshot - Yahoo Finance
Gilead hikes full-year sales outlook, quarterly HIV sales rise 18% - Yahoo Finance
Breakfast News: Brace for an AI Optics Shake-up - The Motley Fool
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial - GlobeNewswire Inc.
Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research
Gilead Sciences earnings: what to look for from GILD - Yahoo Finance
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
Gilead to Report Q3 Earnings: How Should You Play the Stock Now? - Zacks Investment Research
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research
Gilead Sciences, Inc. (GIS.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Gilead Stock Increasing Your Market Risk? - Trefis
What Would A Biktarvy Slowdown Do To Gilead Stock? - Trefis
Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet
BHC Q3 Earnings Preview: Here's What You Should Know - Zacks Investment Research
Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet
Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? - Benzinga
Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
Gilead Sciences, Inc. $GILD Stock: Citizens Financial Group Inc. RI Increases Stake - MarketBeat
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - Yahoo Finance
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - The Motley Fool
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
Gilead expands in I&I with $1.28B Pepstar deal for oral IL-23Ri - BioWorld News
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche - Pharmaceutical Executive
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar - BioSpace
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Oct 15 '26 |
Sale |
156.22 |
3,000 |
468,660 |
113,684 |
| JOHANNA MERCIER | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| Dickinson Andrew D | Chief Financial Officer |
Oct 15 '26 |
Sale |
156.22 |
3,000 |
468,660 |
161,096 |
| ANDREW DICKINSON | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Oct 01 '26 |
Sale |
147.90 |
15,000 |
2,218,508 |
566,683 |
| ANDREW DICKINSON | Officer |
Sep 15 '26 |
Proposed Sale |
145.29 |
3,000 |
435,870 |
0 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
| Dickinson Andrew D | Chief Financial Officer |
Sep 15 '26 |
Sale |
145.29 |
3,000 |
435,870 |
164,096 |
| JOHANNA MERCIER | Officer |
Sep 15 '26 |
Proposed Sale |
144.22 |
3,000 |
432,646 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Sep 01 '26 |
Sale |
148.64 |
15,000 |
2,229,592 |
577,133 |
2.20%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):